CompletedPhase 2

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Japan45 participantsStarted 2009-09

Plain-language summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Has corneal epithelial defect and decreased corneal sensitivity. * Has undergone continuous treatment for corneal epithelial defect for 1 week or longer. Exclusion Criteria: * Presence of disease such as active ocular infection, or abnormal lid closure. * History or presence of chemical burn, Stevens - Johnson Syndrome, etc. * History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.

What they're measuring

Restoration of corneal epithelial defect

Timeframe: Every week

Trial details

NCT IDNCT00988494

SponsorSanten Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Persistent Corneal Epithelial Defect trials